| Literature DB >> 23049706 |
Cornelis P C de Jager1, Peter C Wever, Eugenie F A Gemen, Ron Kusters, Arianne B van Gageldonk-Lafeber, Tom van der Poll, Robert J F Laheij.
Abstract
STUDYEntities:
Mesh:
Substances:
Year: 2012 PMID: 23049706 PMCID: PMC3462173 DOI: 10.1371/journal.pone.0046561
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics upon presentation at the Emergency Department (n = 395).
| Overall | Hospital admission | ICU admission | In-hospital mortality | ||
| (n = 395) | (n = 346) | (n = 31) | (n = 23) | ||
| Age | 18-49 years | 95 (24) | 73 (21) | 5 (16) | 0 |
| 50-64 years | 92 (23) | 81 (23) | 10 (32) | 0 | |
| 65-74 years | 98 (25) | 87 (25) | 9 (29) | 4 (17) | |
| ≥75 years | 110 (28) | 105 (31) | 7 (23) | 19 (83) | |
| Gender | Male | 240 (61) | 210 (61) | 20 (65) | 15 (65) |
| Smoking | Yes | 151 (38) | 129 (37) | 15 (48) | 5 (22) |
| Comorbidity | Diabetes mellitus | 68 (17) | 65 (19) | 9 (29) | 4 (17) |
| Malignancy | 49 (12) | 45 (13) | 4 (13) | 2 (9) | |
| Cardiac | 94 (24) | 88 (25) | 11 (35) | 14 (61) | |
| Cerebrovascular | 48 (12) | 46 (13) | 4 (13) | 4 (17) | |
| Renal | 37 (9) | 36 (10) | 3 (10) | 5 (22) | |
| Hepatic | 17 (4) | 16 (5) | 2 (6) | 1 (4) | |
| COPD | 131 (33) | 124 (36) | 15 (48) | 12 (52) | |
| Medication | Oral corticosteroids | 53 (13) | 48 (14) | 4 (13) | 6 (26) |
| Antibiotics | 148 (37) | 122 (35) | 6 (19) | 9 (39) | |
| Bronchodilators | 130 (33) | 123 (36) | 16 (52) | 13 (56) | |
| Pathogen |
| 73 (18) | 66 (19) | 14 (45) | 5 (22) |
|
| 63 (16) | 48 (14) | 1 (3) | 0 | |
|
| 52 (13) | 44 (13) | 3 (10) | 2 (9) | |
|
| 23 (6) | 22 (6) | 1 (3) | 1 (4) | |
| Influenza A (H1N1) virus | 21 (5) | 18 (5) | 1 (3) | 0 |
COPD, chronic pulmonary obstructive disease; Chronic Obstructive Pulmonary Disease (COPD) was classified using the global initiative for chronic obstructive lung disease classification (GOLD), Hepatic means liver disease related to malignancy, hepatitis, auto-immune liver disease and/or alcoholic liver disease, cardiac means heart disease related to acute coronary syndrome (cardiovascular disease), valvular disease and/or heart failure, renal means renal disease including current renal replacement therapy, cerebrovascular means cerebrovascular disease; n, number; ICU, intensive care unit; data are presented as number (percentage) of patients.
Figure 1Admission levels of the neutrophil-lymphocyte count ratio, white blood cell count (×10e9/l) and C-reactive protein level (mg/l) in community-acquired pneumonia patients classified into five CURB-65 categories (0, 1, 2, 3 and 4+5), (NLCR, neutrophil-lymphocyte count ratio; WBC, white blood cell; Y-axis left CRP, C-reactive protein; Y-axis right) data are presented as mean and SD.
Infection markers in patients admitted to the Emergency Department with community-acquired pneumonia and subpopulations of patients admitted to the hospital and patients deceased during hospitalization.
| CRP (mg/l) | WBC count(10e9/l) | Neutrophil count(10e9/l) | Lymphocyte count(10e9/l) | NLCR | |
| Overall (n = 395) | 171 (128) | 13.5 (6.5) | 11.4 (6.4) | 1.1 (0.7) | 13.6 (12.0) |
| Hospital admission (n = 346) | 181 (130) | 13.9 (6.7) | 11.9 (6.5) | 1.1 (0.6) | 14.4 (12.4) |
| ICU admission (n = 31) | 234 (132) | 16.5 (10.8) | 14.6 (11.1) | 1.1 (0.7) | 18.7 (19.9) |
| In-hospital mortality (n = 23) | 142 (118) | 16.6 (6.0) | 14.4 (5.8) | 1.0 (0.8) | 23.3 (16.8) |
WBC, white blood cell; CRP, C-reactive protein; ICU, intensive care unit; NLCR, neutrophil-lymphocyte count ratio; data are presented as mean (SD).
Frequencies of neutrophil-lymphocyte count ratios <10 and ≥10 in subpopulations of patients admitted to the emergency department with community-acquired pneumonia.
| NLCR <10 | NLCR ≥10 | p-value | ||
| n = 197 | n = 198 | |||
| Age | 18–50 years (n = 95, 24.1%) | 60 (30.5) | 35 (17.7) | <0.01 |
| 50–64 years (n = 92, 23.3%) | 53 (26.9) | 39 (19.7) | 0.09 | |
| 65–74 years (n = 98, 24.8%) | 50 (25.4) | 48 (24.2) | 0.79 | |
| 75 year (n = 110, 27.8%) | 34 (17.2) | 76 (38.4) | <0.01 | |
| Gender | Female (n = 155, 39.2%) | 72 (46.5) | 83 (53.5) | 0.27 |
| Male (n = 240, 60.8%) | 125 (52.1) | 115 (47.9) | ||
| Co-morbidity | COPD (n = 131, 33.2%) | 46 (35.1) | 85 (64.9) | <0.01 |
| Diabetes (n = 68, 17.4%) | 28 (41.2) | 40 (58.8) | 0.11 | |
| Medication | Oral corticosteroids (n = 53, 13.4%) | 23 (43.4) | 30 (56.6) | 0.30 |
| Previous antibiotics (n = 148, 37.5%) | 98 (66.2) | 50 (33.8) | <0.01 | |
| Bronchodilators (n = 130, 32.9%) | 45 (34.6) | 85 (65.4) | <0.01 | |
| Bacteremia | (n = 42, 10.6%) | 9 (21.4) | 33 (78.6) | <0.01 |
| Pathogen |
| 8 (10.9) | 65 (89.1) | <0.01 |
|
| 49 (77.8) | 14 (22.2) | <0.01 | |
|
| 32 (61.5) | 20 (38.5) | 0.07 | |
|
| 11 (47.8) | 12 (52.2) | 0.83 | |
| Influenza A (H1N1) virus (n = 21, 5.3%) | 13 (61.9) | 8 (38.1) | 0.25 | |
| Outcome | ||||
| ICU admission and/or mortality (n = 50, 12.6%) | 13 (26.0) | 37 (74.0) | <0.01 | |
| ICU admission (n = 31, 7.8%) | 9 (29.0) | 22 (71.0) | <0.01 | |
| In-hospital mortality (n = 23, 5.8.%) | 5 (21.7) | 18 (78.3) | <0.01 |
NLCR, neutrophil-lymphocyte count ratio; COPD, chronic pulmonary obstructive disease; ICU, intensive care unit; n, number; data are presented as number (percentage) of patients.
Causative microorganisms of community-acquired pneumonia in the study patients (n = 395).
| Microorganism | Number (%) |
|
| 73 (18.5) |
|
| 63 (15.9) |
|
| 52 (13.2) |
|
| 23 (5.8) |
| Influenza A (H1N1) virus | 21 (5.3) |
|
| 12 (3.0) |
|
| 7 (1.7) |
|
| 3 (0.7) |
|
| 2 (0.5) |
|
| 2 (0.5) |
|
| 7 (1.7) |
| Other gram-negative | 7 (1.7) |
| None | 130 (32.9) |
Figure 2Receiver operating characteristic curves comparing C-reactive protein and the neutrophil-lymphocyte count ratio with respect to prediction of death (NLCR, neutrophil-lymphocyte count ratio; CRP, C-reactive protein).